account_id none on file
legal_name Vor Biopharma Inc.
ticker VOR
cik 1817229
domain vorbio.com
linkedin_company_url https://www.linkedin.com/company/vor-bio
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 11 executives 2 family 0
why_nownone on file
callsnone on file
filings
• costs of consultants, including their fees and related travel expenses; • costs related to compliance with quality and regulatory requirements; • costs of laboratory supplies and acquiring and developing preclinical and clinical trial materials, including expenses associated with our clinical manufacturing organizations (“CMOs”); and • payments made and consideration issued under third party licensing agreeme
filing / Aug 11, 2026 / receipt
-related services and other consulting fees, facility-related expenses, which include depreciation costs and other allocated expenses for rent and maintenance of facilities, insurance costs, recruiting costs, travel expenses and other general administrative expenses.
filing / Aug 11, 2026 / receipt
There was also a decrease of $7.1 million in salaries and benefits expenses primarily due to severance costs incurred in connection with employee terminations in the prior year period.
filing / Aug 11, 2026 / receipt
There was also a decrease of $12.7 million in salaries and benefits expenses primarily due to severance costs incurred in connection with employee terminations in the prior year period, and also due in part to a decreased headcount compared to the prior year period.
filing / Aug 11, 2026 / receipt
Contractual obligations relate to future minimum lease payments for an existing non-cancellable lease relating to corporate office space, with a term expiring in August 2031.
filing / Aug 11, 2026 / receipt
In August 2025, the Company entered into a lease agreement for office space (“Boylston Lease”) with 500 Boylston & 222 Berkeley Owner (DE) LLC (the “Boylston Landlord”).
filing / Aug 11, 2026 / receipt
• costs of consultants, including their fees and related travel expenses; • costs related to compliance with quality and regulatory requirements; • costs of laboratory supplies and acquiring and developing preclinical and clinical trial materials, including expenses associated with our clinical manufacturing organizations (“CMOs”); and • payments made and consideration issued under third party licensing agreeme
filing / May 13, 2026 / receipt
-related services and other consulting fees, facility-related expenses, which include depreciation costs and other allocated expenses for rent and maintenance of facilities, insurance costs, recruiting costs, travel expenses and other general administrative expenses.
filing / May 13, 2026 / receipt
Contractual obligations relate to future minimum lease payments for an existing non-cancellable lease relating to corporate office space, with a term expiring in August 2031.
filing / May 13, 2026 / receipt
In August 2025, the Company entered into a lease agreement for office space (“Boylston Lease”) with 500 Boylston & 222 Berkeley Owner (DE) LLC (the “Boylston Landlord”).
filing / May 13, 2026 / receipt
Digital Technology Lead - Data and AI
company_statement / Jul 1, 2026 / receipt
executives
| Qing Zuraw | Chief Development Officer | - | receipt |
| Sandesh Mahatme | Chief Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changes
| 2025-07-22 | Chief Development Officer, appointed | sec_8k |
| 2025-07-10 | Chief Financial Officer, appointed | sec_8k |
mcp_package_hint
slug vor-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$